|
EP2961768A1
|
|
Immunogenic composition for mers coronavirus infection
|
|
WO2014127231A1
|
|
Oligomeric influenza immunogenic compositions
|
|
US2013203090A1
|
|
Systems and methods for determining antibody-mediated risk index
|
|
US2013209431A1
|
|
Isolation and culture of erythroid progenitor cells
|
|
EP2753176A1
|
|
Hiv inhibitors
|
|
CA2828015A1
|
|
Megakaryocyte and platelet production from stem cells
|
|
AU2012200580A1
|
|
Stabilized therapeutic small helical antiviral peptides
|
|
CA2766417A1
|
|
Stabilized therapeutic small helical antiviral peptides
|
|
WO2012064754A2
|
|
Component preparation system
|
|
WO2012061317A1
|
|
Blood bank management and rapid blood type determination system
|
|
WO2012054745A1
|
|
Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
|
|
WO2011150400A1
|
|
Nuclear scaffold protein stip/tfip11 target for cancer therapy
|
|
CN102883740A
|
|
Bifunctional molecules for inactivating HIV and blocking HIV
|
|
WO2011162873A1
|
|
System and methods for enhanced protection during blood tubing sealing
|
|
CN102665755A
|
|
Immunopotentiator-linked oligomeric influenza immunogenic compositions
|
|
CA2772049A1
|
|
Wd repeat 79 protein targeted therapy
|
|
CA2765197A1
|
|
Ordered assembly of membrane proteins during differentiation of erythroblasts
|
|
WO2010096813A1
|
|
Krüppel-like factors and fat regulation
|
|
EP2393507A2
|
|
Trimerich hiv fusion inhibitors for treating or preventing hiv infection
|
|
WO2010022288A1
|
|
High throughput system for cfu assay by the use of high resolution digital imaging, differential staining and automated laboratory system
|
